Binxia Chang, Ming‐Jiang Xu, Zhou Zhou, Yan Cai, Man Li, Wei Wang, Dechun Feng, Adeline Bertola, Hua Wang, George Kunos, Bin Gao – 29 May 2015 – Obesity and alcohol consumption often coexist and work synergistically to promote steatohepatitis; however, the underlying mechanisms remain obscure. Here, we demonstrate that feeding mice a high‐fat diet (HFD) for as little as 3 days markedly exacerbated acute ethanol binge–induced liver neutrophil infiltration and injury. Feeding mice with an HFD for 3 months plus a single binge of ethanol induced much more severe steatohepatitis.

Ângelo Zambam de Mattos, Angelo Alves de Mattos – 29 May 2015

Binxia Chang, Ming‐Jiang Xu, Zhou Zhou, Yan Cai, Man Li, Wei Wang, Dechun Feng, Adeline Bertola, Hua Wang, George Kunos, Bin Gao – 29 May 2015 – Obesity and alcohol consumption often coexist and work synergistically to promote steatohepatitis; however, the underlying mechanisms remain obscure. Here, we demonstrate that feeding mice a high‐fat diet (HFD) for as little as 3 days markedly exacerbated acute ethanol binge–induced liver neutrophil infiltration and injury. Feeding mice with an HFD for 3 months plus a single binge of ethanol induced much more severe steatohepatitis.

Travis B. Dick, Lance S. Lindberg, Debra D. Ramirez, Michael R. Charlton – 29 May 2015 – The US Food and Drug Administration has recently approved a number of new direct‐acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug‐drug interactions. These interactions must be considered both when starting and stopping any medication, including over‐the‐counter medications and herbal supplements.

Kheng Choon Lim, Pierce K.H. Chow – 29 May 2015

Travis B. Dick, Lance S. Lindberg, Debra D. Ramirez, Michael R. Charlton – 29 May 2015 – The US Food and Drug Administration has recently approved a number of new direct‐acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug‐drug interactions. These interactions must be considered both when starting and stopping any medication, including over‐the‐counter medications and herbal supplements.

David E. Kleiner – 27 May 2015 – Watch a video presentation of this article

David E. Kleiner – 27 May 2015 – Watch a video presentation of this article

Amy G. Feldman, Ronald J. Sokol, – 27 May 2015 – Watch a video presentation of this article

Anna Hadjihambi, Rajiv Jalan – 27 May 2015 – Watch a video presentation of this article